Skip to main content

Doubts about vaccination strategy, soaring vacancies

Australian scientists are proposing a halt in the rollout of the AstraZeneca/Oxford vaccine, which forms the bulk of available vaccine doses in Australia, because its lower effectiveness compared to other vaccines may prevent the country from reaching herd immunity. The key point though is that the AstraZeneca vaccine is as effective in preventing hospitalisations and severe cases of COVID-19 as other available vaccines. The upshot is that the government will press ahead with the rollout and with reopening the economy by Q2 once vulnerable groups have been inoculated.

Become a client to read more

This is premium content that requires an active Capital Economics subscription to view.

Already have an account?

You may already have access to this premium content as part of a paid subscription.

Sign in to read the content in full or get details of how you can access it

Register for free

Sign up for a free account to gain:

  • Unlock additional content
  • Register for Capital Economics events
  • Receive email updates and economist-curated newsletters
  • Request a free trial of our services

Get access